Fulphila
Payments companies reported to CMS as associated with Fulphila. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Fulphila, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Fulphila
These are the largest totals companies reported as associated with Fulphila. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Miguel Regueiro | Pittsburgh, PA | $2,850.00 | |
| Stephen Hanauer | Chicago, IL | Gastroenterology (Internal Medicine) | $2,754.00 |
| Mohsen Arani | The Woodlands, TX | Hematology & Oncology | $277.34 |
| David Tamura | Honolulu, HI | Hematology & Oncology | $50.14 |
| Melvin Palalay | Honolulu, HI | Hematology & Oncology | $50.14 |
| Jennifer Cudris Maldonado | Aventura, FL | Hematology & Oncology | $48.03 |
| Gabriel Domenech | Plantation, FL | Hematology & Oncology | $48.03 |
| Leslie Gutierrez | Houston, TX | Acute Care (Nurse Practitioner) | $45.40 |
| Jana Rains | Shreveport, LA | Nurse Practitioner | $43.52 |
| Robert Massingill | Bossier City, LA | Hematology & Oncology | $43.52 |
Prescribed Fulphila?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.